Review
Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C
Affiliations
- PMID: 22335095
Item in Clipboard
Review
Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C
JNMA J Nepal Med Assoc.
2011 Jan-Mar.
Abstract
Until HCV NS3/4A protease inhibitors become available at the end of 2011, the combination pegylated-interferon (PEG-IFN)-alfa and ribavirin (RBV) will remain the standard treatment for chronic hepatitis C patients. In some hepatitis C virus-infected patients, PEG-IFN plus RBV treatment against HCV should continue to be used because of side effects of new drugs such as anemia. Our Japanese experiences should provide new information for the treatment of chronic hepatitis C.
Similar articles
-
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.Hepatology. 2009 Dec;50(6):1719-26. doi: 10.1002/hep.23204. Hepatology. 2009. PMID: 19852040 Clinical Trial.
-
Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.Enferm Infecc Microbiol Clin. 2013 Aug-Sep;31(7):424-9. doi: 10.1016/j.eimc.2012.12.004. Epub 2013 Feb 28. Enferm Infecc Microbiol Clin. 2013. PMID: 23453582
-
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.Lancet. 2014 Aug 2;384(9941):403-13. doi: 10.1016/S0140-6736(14)60494-3. Epub 2014 Jun 4. Lancet. 2014. PMID: 24907225 Clinical Trial.
-
Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C.J Viral Hepat. 2004 May;11(3):191-7. doi: 10.1111/j.1365-2893.2004.00506.x. J Viral Hepat. 2004. PMID: 15117320 Review.
-
[Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].Orv Hetil. 2011 Dec 11;152(50):1997-2009. doi: 10.1556/OH.2011.29266. Orv Hetil. 2011. PMID: 22112373 Review. Hungarian.
Cited by
-
IFNL4 polymorphism as a predictor of chronic hepatitis C treatment efficiency in Ukrainian patients.Cytol Genet. 2016;50(5):330-333. doi: 10.3103/S0095452716050066. Epub 2016 Oct 11. Cytol Genet. 2016. PMID: 32214544 Free PMC article.